Eli Lilly and Co LLY:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 07/05/24 EDT

916.01

+1.44 (+0.16%)

Volume

161,803

914.57

+16.47 (+1.83%)

Volume

2,683,136

52 week range

434.34 - 918.50

Open898.42
Day High916.46
Day Low896.90
Prev Close898.10
52 Week High918.50
52 Week High Date07/03/24
52 Week Low434.34
52 Week Low Date07/13/23

Key Stats

Market Cap869.212B
Shares Out950.41M
10 Day Average Volume3.03M
Dividend5.20
Dividend Yield0.57%
Beta0.41
YTD % Change56.89

KEY STATS

Open898.42
Day High916.46
Day Low896.90
Prev Close898.10
52 Week High918.50
52 Week High Date07/03/24
52 Week Low434.34
52 Week Low Date07/13/23
Market Cap869.212B
Shares Out950.41M
10 Day Average Volume3.03M
Dividend5.20
Dividend Yield0.57%
Beta0.41
YTD % Change56.89

RATIOS/PROFITABILITY

EPS (TTM)6.79
P/E (TTM)134.62
Fwd P/E (NTM)61.98
EBITDA (TTM)12.912B
ROE (TTM)51.15%
Revenue (TTM)35.932B
Gross Margin (TTM)80.16%
Net Margin (TTM)17.08%
Debt To Equity (MRQ)204.58%

EVENTS

Earnings Date08/08/2024(est)
Ex Div Date08/15/2024
Div Amount1.30
Split Date-
Split Factor-

Latest On Eli Lilly and Co

This ETF is trying to satisfy appetites for weight loss stocks20 Hours AgoCNBC.com
Investors want proof AI will aid drug discovery. More evidence may be on the way23 Hours AgoCNBC.com
Top 5 things to watch in the stock market Friday, including big jobs reportJuly 5, 2024CNBC.com
Wall Street firm gets it right with Best Buy call, plus Eli Lilly shares move upJuly 3, 2024CNBC.com
Wednesday, July 3, 2024: The Club is trimming its position in this beer makerJuly 3, 2024CNBC.com

Content From Our Affiliates

Ozempic shown in JAMA study to lower obesity-associated cancer riskJuly 5, 2024TipRanks
Eli Lilly call volume above normal and directionally bullishJuly 5, 2024TipRanks
Morgan Stanley says impact to Lilly GLP-1 opportunity from NAION link ‘very low’July 5, 2024TipRanks
Eli Lilly’s Kisunla Launch: A Cautious Hold Amid Competitive and Logistical UncertaintiesJuly 4, 2024TipRanks
BMO: Eli Lilly’s (NYSE:LLY) Alzheimer’s Drug Could Boost Sales by $7.1BJuly 3, 2024TipRanks

Profile

Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz....

David Ricks

Chairman of the Board, President, Chief Executive Officer

Diogo Rau

Executive Vice President, Chief Information and Digital Officer

Patrik Jonsson

Executive Vice President, President of Lilly Diabetes and Obesity and President of Lilly USA

Alonzo Weems

Executive Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer

Anat Hakim

Executive Vice President, General Counsel, Secretary

Address

Lilly Corporate Ctr

Drop Code 1094, Lilly Corporate Ctr

Indianapolis, IN

46285-0001

United States

https://www.lilly.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
ABBV AbbVie Inc	167.25	+3.41	+2.08%
MRK Merck & Co Inc	126.45	+0.60	+0.48%
JNJ Johnson & Johnson	146.48	+0.79	+0.54%
AZN AstraZeneca PLC	77.34	+0.54	+0.70%
NVS Novartis AG	108.13	+1.35	+1.26%